drugset / Trial / NCT01466764

Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain

NCT01466764

Terminated 13 enrolled Stanford University
RandomizedParallel-groupTriple-blindTreatment

Summary

The investigators hypothesize that perioperative administration of anakinra will reduce incisional pain by lowering the concentration of inflammatory mediators in surgical wounds. This knowledge is important because it suggests a new, previously unexplored pharmacological target for the control of postoperative incisional pain.

Timeline

Start
2011-10
Primary completion
2013-05
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anakinra Protein / enzyme biologic 100 mg Subcutaneous

Indications

No indication recorded.